In 2023, around 17 percent of men in the United States received mental health treatment or counseling in the past year. The share of men who have received treatment for mental health problems has increased over the past couple decades likely due to a decrease in stigma around seeking such help and increased awareness of mental health issues. However, women in the U.S. are still much more likely to receive mental health treatment than men. Mental illness among men No one is immune to mental illness and the impact of mental health problems can be severe and debilitating. In 2023, it was estimated that 19 percent of men in the United States had some form of mental illness in the past year. Two of the most common mental disorders among men and women alike are anxiety disorders and depression. Depression is more common among men in their late teens and early 20s, with around 15 percent of U.S. men aged 21 to 25 years reporting experiencing a major depressive episode in the past year as of 2022. Depression is a very treatable condition, but those suffering from depression are at a much higher risk of suicide than those who do not have depression. Suicide among men Although women in the United States are more likely to report suffering from mental illness than men, the suicide rate among U.S. men is around 3.7 times higher than that of women. Suicide deaths among men are much more likely to involve the use of firearms, which may explain some of the disparity in suicide deaths between men and women. In 2020, around 58 percent of suicide deaths among men were from firearms compared to just 33 percent of suicide deaths among women. Although more people in the United States are accessing mental health, barriers to treatment persist. In 2022, the thought that they could handle the problem without treatment was the number one reason U.S. adults gave for not receiving the mental health treatment they required.

In 2023, it was estimated that 28.5 percent of U.S. women received mental health treatment or counseling at some time in the past year. This statistic shows the percentage of U.S. women who received mental health treatment or counseling in the past year from 2002 to 2023.

In 2023, around 59.2 million adults in the United States received treatment or counseling for their mental health within the past year. Such treatment included inpatient or outpatient treatment or counseling, or the use of prescription medication. Anxiety and depression are two common reasons for seeking mental health treatment. Who most often receives mental health treatment? In the United States, women are almost twice as likely than men to have received mental health treatment in the past year, with around 21 percent of adult women receiving some form of mental health treatment in the past year, as of 2021. Considering age, those between 18 and 44 years are more likely to receive counseling or therapy than older adults, however older adults are more likely to take medication to treat their mental health issues. Furthermore, mental health treatment in general is far more common among white adults in the U.S. than among other races or ethnicities. In 2020, around 24.4 percent of white adults received some form of mental health treatment in the past year compared to 15.3 percent of black adults and 12.6 percent of Hispanics. Reasons for not receiving mental health treatment Although stigma surrounding mental health treatment has declined over the last few decades and access to such services has greatly improved, many people in the United States who want or need treatment for mental health issues still do not get it. For example, it is estimated that almost half of women with some form of mental illness did not receive any treatment in the past year, as of 2022. Sadly, the most common reason for U.S. adults to not receive mental health treatment is that they thought they could handle the problem without treatment. Other common reasons for not receiving mental health treatment include not knowing where to go for services or could not afford the costs.

In the United States, the prevalence of mental illness in the past year is more common among females than males and more common among the young than the old. As of 2023, some 26.4 percent of females reported some type of mental illness in the past year, compared to 19 percent of males. Common forms of mental illness include depression, anxiety disorders, and mood disorders. Depression Depression is one of the most common mental illnesses in the United States. Depression is defined by prolonged feelings of sadness, hopelessness, and despair leading to a loss of interest in activities once enjoyed, a loss of energy, trouble sleeping, and thoughts of death or suicide. It is estimated that around five percent of the U.S. population suffers from depression. Depression is more common among women with around six percent of women suffering from depression compared to four percent of men. Mental illness and substance abuse Data has shown that those who suffer from mental illness are more likely to suffer from substance abuse than those without mental illness. Those with mental illness are more likely to use illicit drugs such as heroin and cocaine, and to abuse prescription drugs than those without mental illness. As of 2023, around 7.9 percent of adults in the United States suffered from co-occuring mental illness and substance use disorder.

This statistic displays the types of counselling or therapy currently being received in England in 2014, by gender. Of respondents, 31 percent of men and 48 percent of women were receiving counselling (which also includes bereavement counselling).

Bio-identical Hormone Replacement Therapy Market Outlook

The global bio-identical hormone replacement therapy (BHRT) market size is poised to witness significant growth, with a market value of approximately USD 3.5 billion in 2023 projected to escalate to around USD 4.9 billion by 2032. This represents a compound annual growth rate (CAGR) of 3.8% during the forecast period. The increasing awareness about hormonal imbalances and their impact on health, coupled with a growing aging population, are pivotal factors driving the market's expansion. Furthermore, advancements in pharmaceutical technology and a rising preference for bio-identical hormones over synthetic ones further contribute to this positive growth trajectory.

A key growth factor in the bio-identical hormone replacement therapy market is the rising awareness and understanding of hormonal health among the global population. With an increasing number of individuals experiencing hormonal imbalances due to various factors such as aging, lifestyle changes, and environmental influences, there is a growing demand for effective treatments. Bio-identical hormones, which are chemically identical to those the human body produces, offer a more natural and personalized approach, appealing to those seeking alternatives to synthetic hormones. Educational campaigns and healthcare provider endorsements have played a significant role in elevating the awareness and acceptance of BHRT.

The aging population is another fundamental driver catalyzing the demand for bio-identical hormone replacement therapy. As life expectancy increases, a significant portion of the global population is entering age groups where hormonal imbalances are more prevalent, such as menopause in women and andropause in men. This demographic shift has led to a surge in the demand for hormone replacement solutions that can alleviate symptoms such as hot flashes, fatigue, mood swings, and other age-related hormonal deficiencies. Moreover, with increased longevity, maintaining a higher quality of life becomes paramount, prompting many to seek natural hormone therapy options.

Technological advancements and innovations in pharmaceutical formulations have significantly bolstered the bio-identical hormone replacement therapy market. New delivery systems, such as advanced transdermal patches and long-acting injections, have improved the efficacy and convenience of hormone therapies. These innovations not only enhance patient compliance but also expand the market reach by catering to the varied preferences and medical needs of patients. Additionally, biotechnology advancements have facilitated more precise and individualized hormone therapies, aligning with the broader trend toward personalized medicine, which is expected to sustain market growth in the coming years.

Women Health Therapeutics is becoming an increasingly important focus within the bio-identical hormone replacement therapy market. As more women seek solutions for managing hormonal imbalances, particularly during menopause, there is a growing demand for therapies that address their unique health needs. Bio-identical hormones offer a natural alternative that aligns with the body's chemistry, providing relief from symptoms like hot flashes, mood swings, and fatigue. This trend is supported by a broader movement towards personalized medicine, where treatments are tailored to individual health profiles, enhancing both efficacy and patient satisfaction. The emphasis on women’s health is expected to drive innovation and expand the market, as healthcare providers and pharmaceutical companies work to develop therapies that cater specifically to female patients.

Regionally, North America dominates the bio-identical hormone replacement therapy market, with a significant market share attributed to the high prevalence of hormonal disorders, robust healthcare infrastructure, and strong consumer awareness. The European market follows closely, driven by similar factors, along with supportive regulatory environments for bio-identical treatments. The Asia Pacific region is set to exhibit the highest growth rate, as increasing healthcare expenditure, rising awareness, and improving healthcare access fuel market demand. Latin America and the Middle East & Africa, though currently smaller markets, are anticipated to grow steadily as awareness and access to BHRT improve over time.

Product Type Analysis

The product type segment of the bio-identical hormone replacement t

The size of the Seasonal Affective Disorder Therapeutics Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 5.90% during the forecast period. Seasonal Affective Disorder, or SAD, has been described as one of the forms of depressions that appear to come and go with the seasons during typically shorter winter months. This means that individuals experiencing this disorder have symptoms of sadness and hopelessness and have very low energy, and most of all, increased appetite. SAD affects both men and women, though the rate is very high among people who live outside the equatorial area; the disorder is triggered when the day is shorter during a particular season. The treatment market for SAD has been running up for several decades because of the increased publicity by the general public about the disease and its subsequent remedies. Treatment therapy consists mainly of light therapy, medications, and psychotherapy. Light therapy involves broad-spectrum bright light exposure, which is usually gained using a light box that replicates daylight. In some cases, medications that contain antidepressants also are used as part of the treatment management of SAD. Psychotherapy, in this case, more specifically cognitive-behavioral therapy, is also able to help them learn ways of coping with the disorder and work with unadaptive thinking styles associated with SAD. The incidence of SAD is rising; with such an increase in incidence, the need for proper treatments increases with time. At present, R&D is mainly focused on discovery of new therapies: hopefully more targeted drugs than hitherto discovered. Due to enhanced awareness and treatments, as well as this highly essential need for correct mental care, the global therapeutics market of SAD will be expected to expand significantly in the near couple of years. Recent developments include: October 2022: Bausch Health Companies Inc. implemented changes to the Tabular Index for the prevention and treatment of SAD as per the Centers for Medicare & Medicaid Services (CMS) guidelines. Consequently, all relevant codes have been consolidated into a unified bundle for SAD. This modification facilitates healthcare professionals in providing a more straightforward diagnosis through an easily accessible index tab, condensing all SAD diagnoses into one simplified code: F33., February 2022: Granules India received approval from the United States Food and Drug Administration to market Bupropion Hydrochloride extended-release tablets in the United States to treat major depressive disorder and seasonal affective disorder.. Key drivers for this market are: Increasing Prevalence of Seasonal Affective Disorder and Depression, Growing R&D Activities and Rising Number of Treatment Options. Potential restraints include: Lack of Awareness Across Regions, Probable Side Effects and Risks. Notable trends are: Bipolar Disorder Segment Holds Significant Share in the Seasonal Affective Disorder Therapeutics Market.

Abstract Background. Major Depressive Disorder (MDD) is known as a stress-related disease which affects women more often than men. Music therapy (MT) has been shown to be effective in the treatment of MDD. However, clinical trials investigating the effects of MT on psychological and psychobiological stress-related outcomes in women suffering from MDD are still scarce. Methods. This study was conducted as a randomized controlled trial, with participants assigned to either an intervention group (IG), which received group MT (GMT), or a waitlist control group (CG) which received GMT 6 months later. The primary objective was to assess the impact of GMT on psychological stress outcomes (chronic stress, stress coping, and stress experienced in daily life) and psychobiological stress markers (diurnal salivary cortisol levels and circadian heart rate variability), considering the effects of both group allocation and time. Outcome measurements were taken before, immediately after, and for some variables, 10 weeks following the intervention period. Results. A total of 102 women between 18 and 65 years diagnosed with current MDD took part in the study. Overall, the IG demonstrated more substantial stress-reducing effects compared to the CG. Significant improvements were observed in general stress coping, positive thinking, daily life stress, and cortisol. Conclusion. GMT is a cost-effective and non-invasive approach to effectively address the stress-related psychological and psychobiological burden associated with MDD. To demonstrate long-term effects and gain a better understanding of the underlying mechanisms, further methodologically robust studies are needed.

This special topic poll, fielded May 19-22, 1997, is part of a continuing series of monthly surveys that solicit public opinion on the presidency and on a range of other political and social issues. The focus of this data collection was men's and women's health issues. Respondents were asked about health-related topics such as what they thought was the leading cause of death for women, the perceived differences in men's and women's health and their interactions with their doctors, what they thought were the most serious diseases or medical problems facing the country, and whether they thought the federal government spends more money researching health problems as they relate to men or more money researching health problems as they relate to women. Female respondents were polled on whether a doctor had ever discussed mammograms with them, whether they ever had a mammogram, how trustworthy, safe, and painful mammograms were, at which age women should begin getting mammograms, and how often they conducted breast self-examinations. All respondents were asked whether they tried alternative medicine, whether they had considered trying alternative medicine, and whether they would choose alternative medicine instead of traditional medicine. A series of questions were asked about the type of interactions respondents had with their doctors such as whether respondents felt intimidated by their doctors, how comfortable respondents felt asking their doctors a lot of questions, whether respondents thought their doctors spoke down to them, and whether respondents usually call their doctors by their first name. Respondent's views were also sought on other topics such as the respondent's state of health, menopause, and hormone replacement therapy. Demographic variables included sex, age, race, education level, employment status, presence of children and teenagers in the household, household income, marital status, political party affiliation, political philosophy, type of residential area (e.g., urban or rural), and religious preference.

Estrogen Replacement Therapy Market Outlook

The global market size for Estrogen Replacement Therapy (ERT) was estimated at USD 9.4 billion in 2023 and is projected to reach USD 15.1 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.2% over the forecast period. This market is poised for robust expansion driven by increasing awareness of menopausal health, advances in hormonal treatment technologies, and rising incidences of conditions like osteoporosis and hypogonadism that necessitate hormone replacement therapy.

One of the primary growth factors for the ERT market is the growing awareness about menopausal health. As more educational resources become available and healthcare providers emphasize the importance of managing menopausal symptoms, more women are turning to estrogen replacement therapy for relief. This increased awareness is not just limited to developed countries but is also spreading in emerging economies, contributing significantly to market growth. Additionally, the aging global population means a larger cohort of women entering menopause, further driving the demand for ERT.

Technological advancements and innovations in hormone replacement therapy have also fueled market growth. Modern ERT products are increasingly focusing on personalized medicine, offering tailored dosages and delivery methods to suit individual patient needs. Innovations such as transdermal patches, gels, and sprays are providing more convenient and controlled methods of estrogen delivery compared to traditional oral pills. This has enhanced patient compliance and satisfaction, thereby propelling market growth.

Hormone Replacement Drugs play a crucial role in modern healthcare, particularly in addressing the symptoms associated with menopause and other hormonal imbalances. These drugs are designed to supplement the body's natural hormone levels, which can decline due to age or medical conditions. By restoring hormonal balance, Hormone Replacement Drugs can alleviate symptoms such as hot flashes, mood swings, and bone density loss, significantly improving the quality of life for many individuals. The development and refinement of these drugs have been pivotal in expanding treatment options and enhancing patient outcomes, making them an integral component of hormone replacement therapy.

The rising incidences of conditions like osteoporosis and hypogonadism also significantly drive the ERT market. Osteoporosis, a condition characterized by weakened bones, is prevalent among postmenopausal women due to reduced estrogen levels. Estrogen replacement therapy helps in maintaining bone density and health, thereby reducing the risk of fractures. Similarly, hypogonadism, a condition where the body produces insufficient sex hormones, can affect both men and women, necessitating hormone replacement therapy.

Regionally, North America is anticipated to hold a significant share of the ERT market due to high healthcare expenditure, advanced healthcare infrastructure, and increased awareness about menopausal health. However, Asia Pacific is expected to be the fastest-growing region owing to increasing healthcare awareness, improving healthcare infrastructure, and a large population base.

Bio-identical Hormones Replacement Therapy has emerged as a popular alternative within the realm of hormone replacement therapies. Unlike traditional synthetic hormones, bio-identical hormones are chemically identical to those the human body naturally produces. This similarity is believed to offer a more natural and potentially safer approach to hormone replacement, with fewer side effects. Patients and healthcare providers are increasingly considering Bio-identical Hormones Replacement Therapy for its personalized treatment potential, tailoring hormone levels to individual needs and preferences. This approach aligns with the growing trend towards personalized medicine, offering a promising avenue for those seeking more natural hormone replacement solutions.

Product Type Analysis

The ERT market is segmented into various product types including oral, transdermal, topical, injectable, and others. Oral estrogen replacement therapy is one of the most traditional and widely used forms of hormone replacement. Pills and tablets are typically taken daily and can be an effective way

ABSTRACT CONTEXT AND OBJECTIVE: Aging causes changes in men and women. Studies have shown that women have worse postural balance and greater functional dependence than men, but there is no consensus regarding this. The aim of this study was to compare the balance and functional independence of elderly people according to sex and age, and to evaluate the association between postural balance and the number of drugs taken. DESIGN AND SETTING: Cross-sectional at a state university. METHODS: 202 elderly people were evaluated regarding balance (Berg Scale), independence (Barthel Index), age, sex, number of medications and physical activity. RESULTS: The subjects comprised 117 women (70.2 ± 5.6 years old) and 85 men (71.1 ± 6.9 years old). For balance, there was no significant difference regarding sex, but there was a difference regarding age (P < 0.0001). For functional independence, there was a difference regarding sex (P = 0.003), but not regarding age. The variables of age, medications and physical activity were significant for predicting the Berg score. For the Barthel index, only age and sex were significant. Elderly people who took three or more medications/day showed higher risk of falling than those who took up two drugs/day (odds ratio = 5.53, P < 0.0001, 95% confidence interval, 2.3-13.0). CONCLUSIONS: There was no sexual difference in relation to postural balance. However, people who were more elderly presented a high risk of falling. Functional dependence was worse among females. There was an association between the number of medication drugs and risk of falling.

IntroductionThis systematic review highlights that schizophrenia (SZ) manifests significant sex differences across neurobiological, clinical, treatment response, and adverse effect domains, underscoring the need for sex-specific considerations in both research and clinical practice.MethodsA systematic search was conducted following PRISMA guidelines, primarily through Pubmed, PsycINFO, Web of Science, and the Cochrane Library. Eligible studies on sex differences in patients with schizophrenia were included. Main search keywords were schizophrenia, sex differences, sex, gender, neurobiology, symptomatology, epidemiology, treatment response, adverse effects.ResultsWhile lifetime prevalence is similar between men and women, the disorder’s trajectory diverges. Men typically experience illness onset approximately 3–5 years earlier than women, with more severe negative symptoms, worse social functioning, and higher rates of comorbid substance use disorders. By contrast, women often have later onset—including a secondary mid-life peak likely linked to declining estrogen—and tend to present with more affective symptoms. Neurobiologically, men with SZ exhibit more extensive structural brain abnormalities and cognitive impairment (especially in memory), whereas women benefit from a degree of neuroprotection possibly mediated by estrogen and distinct gene expression patterns. Hormonal influences appear pivotal, with estrogen’s neuroprotective effects potentially delaying onset and mitigating symptom severity in women, and low testosterone levels correlating with more pronounced negative symptoms in men. Treatment response also varies by sex: women with SZ generally respond to antipsychotics at lower doses with better clinical improvement and fewer relapses, whereas men often require higher doses due to faster drug metabolism and also typically face higher relapse risks. Notably, the treatment advantage of women diminishes after menopause. Adverse effect profiles differ as well: women with SZ are more prone to side effects such as antipsychotic-induced hyperprolactinemia, weight gain, and metabolic or cardiovascular complications, while men tend to experience more neurological side effects while also exhibiting lower treatment adherence.DiscussionThese multidimensional sex differences underscore that all aspects of schizophrenia—from pathophysiology and presentation to therapy and side effect management—must be viewed through a sex-specific lens. Tailoring interventions to the needs of men and women patients is essential for optimizing outcomes and advancing personalized care.

The 1992 Malawi Demographic and Health Survey (MDHS) was a nationally representative sample survey designed to provide information on levels and trends in fertility, early childhood mortality and morbidity, family planning knowledge and use, and maternal and child health. The survey was implemented by the National Statistical Office during September to November 1992. In 5323 households, 4849 women age 15-49 years and 1151 men age 20-54 years were interviewed. The Malawi Demographic and Health Survey (MDHS) was a national sample survey of women and men of reproductive age designed to provide, among other things, information on fertility, family planning, child survival, and health of mothers and children. Specifically, the main objectives of the survey were to: Collect up-to-date information on fertility, infant and child mortality, and family planning Collect information on health-related matters, including breastleeding, antenatal and maternity services, vaccinations, and childhood diseases and treatment Assess the nutritional status of mothers and children Collect information on knowledge and attitudes regarding AIDS Collect information suitable for the estimation of mortality related to pregnancy and childbearing Assess the availability of health and family planning services. MAIN FINDINGS The findings indicate that fertility in Malawi has been declining over the last decade; at current levels a woman will give birth to an average of 6.7 children during her lifetime. Fertility in rural areas is 6.9 children per woman compared to 5.5 children in urban areas. Fertility is higher in the Central Region (7.4 children per woman) than in the Northem Region (6.7) or Southern Region (6.2). Over the last decade, the average age at which a woman first gives birth has risen slightly over the last decade from 18.3 to 18.9 years. Still, over one third of women currently under 20 years of age have either already given birlh to at least one child or are currently pregnant. Although 58 percent of currently married women would like to have another child, only 19 percent want one within the next two years. Thirty-seven percent would prefer to walt two or more years. Nearly one quarter of married women want no more children than they already have. Thus, a majority of women (61 percent) want either to delay their next birth or end childbearing altogether. This represents the proportion of women who are potentially in need of family planning. Women reported an average ideal family size of 5.7 children (i.e., wanted fertility), one child less than the actual fertility level measured in the surveyfurther evidence of the need for family planning methods. Knowledge of contraceptive methods is high among all age groups and socioeconomic strata of women and men. Most women and men also know of a source to obtain a contraceptive method, although this varies by the type of method. The contraceptive pill is the most commonly cited method known by women; men are most familiar with condoms. Despite widespread knowledge of family planning, current use of contraception remains quite low. Only 7 percent of currently married women were using a modem method and another 6 percent were using a traditional method of family planning at the time of the survey. This does, however, represent an increase in the contraceptive prevalence rate (modem methods) from about 1 percent estimated from data collected in the 1984 Family Formation Survey. The modem methods most commonly used by women are the pill (2.2 percent), female sterilisation (1.7 percent), condoms (1.7 percent), and injections (1.5 percent). Men reported higher rates of contraceptive use (13 percent use of modem methods) than women. However, when comparing method-specific use rates, nearly all of the difference in use between men and women is explained by much higher condom use among men. Early childhood mortality remains high in Malawi; the under-five mortality rate currently stands at 234 deaths per 1000 live births. The infant mortality rate was estimated at 134 per 10130 live births. This means that nearly one in seven children dies before his first birthday, and nearly one in four children does not reach his fifth birthday. The probability of child death is linked to several factors, most strikingly, low levels of maternal education and short intervals between births. Children of uneducated women are twice as likely to die in the first five years of life as children of women with a secondary education. Similarly, the probablity of under-five mortality for children with a previous birth interval of less than 2 years is two times greater than for children with a birth interval of 4 or more years. Children living in rural areas have a higher rate ofunder-fwe mortality than urban children, and children in the Central Region have higher mortality than their counterparts in the Northem and Southem Regions. Data were collected that allow estimation ofmatemalmortality. It is estimated that for every 100,000 live births, 620 women die due to causes related to pregnancy and childbearing. The height and weight of children under five years old and their mothers were collected in the survey. The results show that nearly one half of children under age five are stunted, i.e., too short for their age; about half of these are severely stunted. By age 3, two-thirds of children are stunted. As with childhood mortality, chronic undernutrition is more common in rural areas and among children of uneducated women. The duration of breastfeeding is relatively long in Malawi (median length, 21 months), but supplemental liquids and foods are introduced at an early age. By age 2-3 months, 76 percent of children are already receiving supplements. Mothers were asked to report on recent episodes of illness among their young children. The results indicate that children age 6-23 months are the most vulnerable to fever, acute respiratory infection (ARI), and diarrhea. Over half of the children in this age group were reported to have had a fever, about 40 percent had a bout with diarrhea, and 20 percent had symptoms indicating ARI in the two-week period before the survey. Less than half of recently sick children had been taken to a health facility for treatment. Sixty-three percent of children with diarrhea were given rehydration therapy, using either prepackaged rehydration salts or a home-based preparation. However, one quarter of children with diarrhea received less fluid than normal during the illness, and for 17 percent of children still being breastfed, breastfeeding of the sick child was reduced. Use of basic, preventive maternal and child health services is generally high. For 90 percent of recent births, mothers had received antenatal care from a trained medical person, most commonly a nurse or trained midwife. For 86 percent of births, mothers had received at least one dose of tetanus toxoid during pregnancy. Over half of recent births were delivered in a health facility. Child vaccination coverage is high; 82 percent of children age 12-23 months had received the full complement of recommended vaccines, 67 percent by exact age 12 months. BCG coverage and first dose coverage for DPT and polio vaccine were 97 percent. However, 9 percent of children age 12-23 months who received the first doses of DPT and polio vaccine failed to eventually receive the recommended third doses. Information was collected on knowledge and attitudes regarding AIDS. General knowledge of AIDS is nearly universal in Malawi; 98 percent of men and 95 percent of women said they had heard of AIDS. Further, the vast majority of men and women know that the disease is transmitted through sexual intercourse. Men tended to know more different ways of disease transmission than women, and were more likely to mention condom use as a means to prevent spread of AIDS. Women, especially those living in rural areas, are more likely to hold misconceptions about modes of disease transmission. Thirty percent of rural women believe that AIDS can not be prevented.

In 2023 a total of 29,896 registered general psychologists in Australia were female, compared to 7,168 registered general male psychologists. With regard to provisional psychologists, women also outnumbered men.

Hypoactive Sexual Desire Disorder (HSDD) Treatment Market size was valued at USD 1.9 Billion in 2023 and is projected to reach USD 4.3 Billion by 2030, growing at a CAGR of 14 % during the forecast period from 2024-2030.

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Drivers

The market drivers for the Hypoactive Sexual Desire Disorder (HSDD) Treatment Market can be influenced by various factors. These may include:

Growing Awareness: Patients' and healthcare professionals' increasing knowledge of hypoactive sexual desire disorder (HSDD) is fueling the market's expansion. Growing Prevalence: Globally, HSDD is becoming more common in both men and women, which is helping to drive market growth. Technological Developments: The market is expanding due to improvements in treatment modalities and diagnostic methods, including pharmaceutical and non-pharmacological ones. Aging Population: There is an increased need for treatment options due to the aging population's increased susceptibility to sexual dysfunctions, including HSDD, especially in developed nations. Changing Lifestyles: Sexual dysfunctions like HSDD are made worse by modern lifestyles marked by stress, sedentary behavior, and bad eating patterns, which increase the need for treatment. Growing Healthcare Expenditure: More treatment options for HSDD are available due to rising healthcare costs, particularly in emerging economies. Regulatory Support: The market is expanding thanks to regulatory rules that are favorable to the approval and marketing of medications and therapies used in HSDD therapy. Growing Acceptance: People are becoming less stigmatized and more inclined to seek treatment for HSDD as a result of the growing acceptance of sexual health issues as real medical concerns. Patient Education Initiatives: By educating the public about HSDD, advocacy groups and healthcare organizations are increasing awareness and motivating people to get treatment. Strategic Partnerships: The market is expanding as a result of partnerships between pharmaceutical companies and academic institutions to create cutting-edge HSDD treatments.

Hormone Replacement Therapy Market Outlook

According to our latest research, the global hormone replacement therapy (HRT) market size reached USD 21.3 billion in 2024, reflecting robust demand for hormone-based treatments worldwide. The market is expected to register a CAGR of 6.1% from 2025 to 2033, projecting a value of USD 36.2 billion by 2033. This growth is primarily driven by the rising prevalence of hormonal disorders, increased awareness of hormone therapy benefits, and the growing geriatric population. As per our analysis, the market’s momentum is sustained by continual advancements in drug delivery systems and a strong pipeline of novel hormone formulations.

A significant growth factor for the hormone replacement therapy market is the increasing incidence of hormone-related disorders such as menopause, hypothyroidism, and male hypogonadism. The global demographic shift towards an aging population has resulted in a surge of individuals experiencing hormonal imbalances, particularly women undergoing menopause and elderly men with testosterone deficiencies. Additionally, early diagnosis and improved screening rates for endocrine disorders have led to higher treatment adoption rates. The growing acceptance of hormone replacement therapy as a standard treatment modality among healthcare professionals further supports market expansion, as does the increasing inclusion of HRT in clinical guidelines for managing age-associated hormonal deficiencies.

Technological advancements in drug formulation and delivery methods have also played a pivotal role in market growth. The development of novel transdermal patches, gels, and implantable devices has enhanced patient compliance by providing more convenient and less invasive options compared to traditional oral or injectable therapies. Pharmaceutical companies are investing heavily in research and development to create safer, more effective hormone therapies with reduced side effects. These innovations not only improve therapeutic outcomes but also expand the eligible patient pool, thereby driving market growth. The integration of personalized medicine and pharmacogenomics into hormone replacement therapy is further expected to revolutionize treatment protocols, offering tailored solutions that maximize efficacy and minimize risks.

Another key driver is the growing awareness and education regarding the benefits and risks of hormone replacement therapy. Public health initiatives, patient advocacy groups, and healthcare providers are actively disseminating information about the importance of hormonal balance and the therapeutic options available. This has led to a reduction in stigma and misconceptions associated with hormone therapy, encouraging more individuals to seek medical advice and consider HRT as a viable treatment option. Moreover, the expansion of healthcare infrastructure in emerging economies and the increasing availability of hormone therapies through retail pharmacies and online platforms are making these treatments more accessible to a broader population base.

From a regional perspective, North America continues to dominate the hormone replacement therapy market, accounting for the largest share in 2024. This leadership is attributed to high awareness levels, advanced healthcare infrastructure, and a substantial patient population suffering from hormonal disorders. Europe follows closely, supported by favorable reimbursement policies and a strong emphasis on women’s health. The Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing healthcare expenditure, rising awareness, and rapid urbanization. Latin America and the Middle East & Africa are also experiencing steady growth, albeit from a smaller base, as healthcare systems in these regions continue to evolve and adopt modern therapeutic approaches.

Product Type Analysis

The hormone replacement therapy market is segmented by product type into estrogen hormone replacement therapy, human growth hormone replaceme

Snapshot img

Laser Hair Loss Treatment Market Size 2024-2028

The laser hair loss treatment market size is forecast to increase by USD 83.7 million at a CAGR of 5.43% between 2023 and 2028.

The market is experiencing significant growth due to the rising prevalence of conditions such as androgenetic alopecia and pattern baldness. This market is driven by the emergence of personalized treatment plans using advanced technologies like red light therapy, laser caps, and hair growth bands. However, the high cost associated with these treatments remains a challenge for many consumers. Despite this, the market is expected to continue expanding as more individuals seek effective solutions for hair loss. 
Overall, laser hair loss treatment offers a non-surgical alternative to traditional hair restoration drugs and stem cell therapy. The market growth is fueled by the increasing prevalence of hair loss conditions and the emergence of personalized laser treatment plans. However, the high cost of these treatments poses a significant challenge for consumers. Despite this, the market is poised for continued expansion as more individuals seek effective solutions for hair loss.

What will be the Size of the Laser Hair Loss Treatment Market During the Forecast Period?

Request Free Sample

Androgenetic alopecia, also known as pattern baldness, is a common chronic disease that affects both men and women. This condition is characterized by the gradual thinning of hair on the scalp, leading to hair loss. Traditional medical treatments for androgenetic alopecia include hair restoration drugs and surgeries such as scalp reduction. However, in recent years, laser therapy has emerged as a promising alternative for those seeking a non-surgical solution. Laser therapy, specifically red light therapy, has gained popularity in the field of hair restoration. This treatment utilizes low-level laser light to stimulate hair follicles and promote hair growth.
Moreover, two common types of laser therapy devices used for hair loss are laser caps and laser combs. Laser caps are wearable devices that fit over the head and deliver laser light to the scalp. These devices are designed to be used daily and offer the advantage of treating larger areas of the scalp at once. On the other hand, laser combs are handheld devices that are combed through the hair to deliver laser light to the scalp. These devices are more portable and offer more flexibility in terms of usage. The prevalence of androgenetic alopecia is significant, with an estimated 50 million men and 30 million women in the US experiencing hair loss.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Low-level lasers
  Medium-level lasers


Gender

  Men
  Women


Geography

  North America

    US


  Europe

    Germany
    UK


  APAC

    China
    Japan


  South America



  Middle East and Africa

By Type Insights

The low-level lasers segment is estimated to witness significant growth during the forecast period.

Low-level laser therapy is a non-surgical hair loss treatment that utilizes lasers or light-emitting diodes (LED) to stimulate hair growth and inhibit hair loss. This therapy employs red or near-infrared light, which is absorbed by the hair follicles, enhancing cellular metabolism and promoting hair growth. The process is believed to improve blood circulation, decrease inflammation, and extend the anagen phase (hair growth cycle). The popularity of laser hair loss treatment has escalated due to increased awareness about its advantages. Various resources, media coverage, and positive testimonials from individuals have contributed to the growing recognition and acceptance of this treatment. Androgenetic alopecia and pattern baldness are common conditions that can benefit from laser therapy. Laser caps, combs, and hair growth bands are popular devices used for this purpose.

Get a glance at the market report of share of various segments Request Free Sample

The Low-level lasers segment was valued at USD 204.80 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 39% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

In 2023, North America held the largest market share in the global laser hair loss treatment industry. The region's well-established healthcare infrastructure and accessible companies offering various hair loss

Introduction: Medication safety is a vital aim in older adults’ pharmacotherapy. Increased morbidity and vulnerability require particularly careful prescribing. Beneath avoiding unnecessary polypharmacy and prescribing omissions, physicians have to be aware of potentially inappropriate medications (PIMs) and related outcomes to optimize older adults’ drug therapy, and to reduce adverse drug events. Objective: The aim of this study was to identify participants characteristics associated with PIM use and associations of PIM use with functional capacity with a focus on sex differences. Methods: Multivariable logistic regression analyses of cross-sectional Berlin Aging Study II (BASE-II) data (N = 1,382, median age 69 years, interquartile range 67–71, 51.3% women) were performed with PIM classification according to the EU(7)-PIM list. Results: In the overall study population, higher education was associated with lower odds of PIM use (odds ratio [OR] 0.93, confidence interval [CI] 95% 0.87–0.99, p = 0.017). Falls (OR 1.53, CI 95% 1.08–2.17, p = 0.016), frailty/prefrailty (OR 1.68, 1.17–2.41, p = 0.005), and depression (OR 2.12, CI 95% 1.32–3.41, p = 0.002) were associated with increased odds of PIM use. A better nutritional status was associated with lower odds of PIM use (OR 0.88, CI 95% 0.81–0.97, p = 0.008). In the sex-stratified analysis, higher education was associated with lower odds of PIM use in men (OR 0.90, CI 95% 0.82–0.99, p = 0.032). Frailty/prefrailty was associated with increased odds of PIM use in men (OR 2.04, CI 95% 1.18–3.54, p = 0.011) and a better nutritional status was associated with lower odds of PIM use in men (OR 0.83, CI 95% 0.72–0.96, p = 0.011). Falls in the past 12 months were related to an increased prevalence of PIM use in women (OR 1.74, CI 95% 1.10–2.75, p = 0.019). Depression was associated with a higher prevalence of PIM use in both men (OR 2.74, CI 95% 1.20–6.24, p = 0.016) and women (OR 2.06, CI 95% 1.14–3.71, p = 0.017). We did not detect sex differences regarding the overall use of drugs with anticholinergic effects, but more men than women used PIMs referring to the cardiovascular system (p = 0.036), while more women than men used PIMs referring to the genitourinary system and sex hormones (p < 0.001). Conclusion: We found similarities, but also differences between men and women as to the associations between PIM use and participants’ characteristics and functional capacity assessments. The association of lower education with PIM use may suggest that physicians’ prescribing behavior is modified by patient education, a relationship that could evolve from more critical attitudes of educated patients towards medication use. We conclude that sex differences in associations of PIM use with functional capacities might be partly attributable to sex differences in drug classes used, but not with regard to anticholinergics, as these are used to a similar extent in men and women in the cohort studied here.

Drugs for Hormonal Replacement Therapy Market Outlook

The global market size for Drugs for Hormonal Replacement Therapy (HRT) was valued at USD 15.2 billion in 2023 and is projected to reach approximately USD 28.9 billion by 2032, growing at a CAGR of 7.2% during the forecast period. This substantial growth can be attributed to increasing prevalence of hormonal imbalances and rising awareness regarding hormonal replacement therapies.

A key growth factor for the HRT market is the increasing incidence of hormonal-related disorders such as menopause, hypothyroidism, and hypogonadism. As the global population ages, the number of individuals experiencing hormonal imbalances is on the rise, necessitating effective treatment options. Menopause, in particular, is a significant driver, with many women seeking relief from symptoms such as hot flashes, night sweats, and mood swings. This demographic trend is expected to sustain strong demand for HRT drugs over the forecast period.

Technological advancements in drug delivery systems also play a crucial role in market growth. Innovations such as transdermal patches, gels, and new formulations of oral medications offer more convenient and effective ways to administer HRT. These advancements not only improve patient compliance but also enhance the overall effectiveness of the treatments. Pharmaceutical companies are investing heavily in research and development to bring novel products to market, further driving growth in this sector.

Increasing awareness about hormonal health and the benefits of HRT is another significant growth factor. Public health initiatives and educational programs are helping to reduce the stigma associated with hormonal therapy, making it more acceptable and accessible to a broader population. Healthcare providers are also becoming more adept at diagnosing hormonal imbalances and recommending appropriate therapies, contributing to the market's expansion.

Hypogonadism Drug development is becoming increasingly important in the realm of hormonal replacement therapies. Hypogonadism, a condition characterized by low levels of testosterone in men, has seen a rise in diagnosis due to increased awareness and improved diagnostic techniques. As a result, the demand for effective treatment options is growing. Pharmaceutical companies are focusing on creating innovative Hypogonadism Drugs that not only address the symptoms but also improve the quality of life for patients. These drugs are available in various forms, including gels, patches, and injections, offering flexibility and convenience to patients. The advancements in drug formulations and delivery methods are expected to drive significant growth in this segment, as more men seek treatment for this condition.

Regionally, North America is expected to dominate the market, followed by Europe and Asia Pacific. North America's leadership position can be attributed to its advanced healthcare infrastructure, high awareness levels, and significant investment in healthcare. Europe also shows strong growth potential due to increasing aging population and rising incidences of hormonal disorders. Asia Pacific is anticipated to witness the highest growth rate, driven by improving healthcare infrastructure, growing awareness, and increasing disposable incomes.

Product Type Analysis

Estrogen Replacement Therapy (ERT) remains the most widely used form of hormonal replacement therapy. This segment is driven by its efficacy in treating menopausal symptoms, which affect a significant portion of the female population. ERT is available in various forms, including pills, patches, and creams, which offer flexibility to patients in terms of administration. The market for ERT is expected to see robust growth as more women seek treatment for menopause-related symptoms.

Progesterone Replacement Therapy (PRT) is another vital segment, particularly for women who have not undergone a hysterectomy. Progesterone is commonly prescribed alongside estrogen to mitigate the risks associated with estrogen-only therapy, such as endometrial cancer. PRT is often used to address issues like irregular menstrual cycles and to support pregnancy in women facing infertility due to hormonal deficiencies. The versatility and necessity of PRT in comprehensive hormonal treatment plans make it a significant contributor to market growth.

<a href="https://dataintelo.com/report/endocrine-therapy-dru

Europe Hair Loss Treatment Products Market size was valued at USD 186.49 Billion in 2023 and is projected to reach USD 229.20 Billion by 2031 growing at a CAGR of 4.21% from 2024 to 2031.

Key Market Drivers:

Increasing Prevalence of Androgenetic Alopecia: According to a study published in the European Dermatology Journal, over half of men and 40% of women in Europe have some type of hair loss by the age of 50. The European Hair Loss Research Foundation claims that androgenetic alopecia affects over 70 million people in Europe. This high prevalence is fuelling increasing demand for hair loss treatment products, as the industry responds to consumers’ increased desire for effective remedies to genetic hair loss.

Rising Mental Health and Psychological Impact of Hair Loss: The European Mental Health Association emphasis that hair loss can have a substantial influence on psychological well-being, with research indicating that 60% of people who lose their hair report lower self-esteem and higher worry. This psychological factor is pushing the market toward more complete treatment options. According to the European Psychological Research Institute, 45% of people who suffer from hair loss actively seek treatment items, offering a significant market opportunity for hair loss therapy makers.